FindMyKOL
Clinical trialNCT03266965CompletedPhase 1Interventional

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

NCT03266965 is a phase 1 interventional trial sponsored by University of Miami. As of 21 Nov 2026, it is completed. It studies Carbidopa in Multiple Sclerosis. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 23 Mar 2018 and a primary completion date of 7 Aug 2020.

SponsorUniversity of Miami →Enrollment18Multiple Sclerosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03266965
FieldValue
Registry IDNCT03266965
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorUniversity of Miami
Enrollment18
Registered sites1
Countries1
ConditionsMultiple Sclerosis
DrugsCarbidopa
Start23 Mar 2018
Primary completion7 Aug 2020
Study completion7 Aug 2020
Last update posted8 Oct 2020

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The histaminergic system is phylogenetically one of the oldest parts of the nervous system but it is a relatively recent discovery. It is involved with several vegetative functions like sleep, attention and learning, feeding and satiety, working memory, cognition, depression, and most of all arousal and energy

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • University of Miami

    Miami

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03266965

Each answer restates registry values shown on this page.

What is NCT03266965?

NCT03266965 is a phase 1 interventional trial sponsored by University of Miami. It studies Carbidopa in Multiple Sclerosis.

Who leads NCT03266965?

The registry names Kottil Rammohan, MD (principal investigator, University of Miami) as the overall official.

Where does NCT03266965 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03266965 study?

The registered drug and biological interventions are Carbidopa.

When did NCT03266965 end?

The registry lists a primary completion date of 7 Aug 2020 and a study completion date of 7 Aug 2020. The sponsor last updated the record on 8 Oct 2020.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.